Latest Breaking News On - Aerpio pharmaceuticals inc - Page 9 : vimarsana.com

Share this article Share this article NEW YORK, May 19, 2021 /PRNewswire/ WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerpio Pharmaceuticals, Inc. ( Aerpio or the Company ) (NASDAQ: ARPO) in connection with the proposed merger of the Company with privately-held Aadi Bioscience, Inc. ( Aadi ). Under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one combined entity that will trade publicly on the NASDAQ. At close of the transaction, Aadi shareholders are expected to own approximately 66.8% of the newly-combined company, with Aerpio shareholders owning only approximately 33.2%. Following the closing of a concurrent PIPE financing, Aerpio shareholders will own only approximately 14.7% of the combined company.

New yorkUnited statesJoshua rubinAadi bioscience incAerpio pharmaceuticals incPrnewswire weisslawAerpio pharmaceuticalsAadi bioscienceபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்ஜோஷுவா ரூபின்ஆடி உயிர் அறிவியல் இன்க்ஆடி உயிர் அறிவியல்